Imexpharm Corp (STC:IMP) Stock Price, Trades & News

Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	2.31
Equity-to-Asset	0.84
Debt-to-Equity	0.08
Debt-to-EBITDA	0.35
Interest Coverage	21.33
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	11.68	Distress Grey Safe
Beneish M-Score	-2.26	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	14.1
	3-Year EBITDA Growth Rate	16.9
	3-Year EPS without NRI Growth Rate	18.3
	3-Year FCF Growth Rate	-53.9
	3-Year Book Growth Rate	6.8
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	15.28
	Future 3-5Y Total Revenue Growth Rate Estimate	16.99

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	1.84
	9-Day RSI	8
	14-Day RSI	15.25
	3-1 Month Momentum %	-14.5
	6-1 Month Momentum %	-7.72
	12-1 Month Momentum %	-8.98

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	4.55
	Quick Ratio	2.66
	Cash Ratio	1.36
	Days Inventory	177.08
	Days Sales Outstanding	59.88
	Days Payable	30.07

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.17
	Dividend Payout Ratio	0.25
	3-Year Dividend Growth Rate	-8.3
	5-Year Yield-on-Cost %	1.1
	Shareholder Yield %	-0.74

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	41.52
	Operating Margin %	19.49
	Net Margin %	14.9
	EBITDA Margin %	24.23
	FCF Margin %	11.61
	OCF Margin %	12.22
	ROE %	15.85
	ROA %	12.29
	ROIC %	16.56
	3-Year ROIIC %	24.64
	ROC (Joel Greenblatt) %	25.42
	ROCE %	19.57
	Years of Profitability over Past 10-Year	10

GF Value Rank

9/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	46.58
	Forward PE Ratio	17.22
	PE Ratio without NRI	20.67
	Shiller PE Ratio	33.3
	Price-to-Owner-Earnings	17.08
	PEG Ratio	1.46
	PS Ratio	3.01
	PB Ratio	2.73
	Price-to-Tangible-Book	2.86
	Price-to-Free-Cash-Flow	25.05
	Price-to-Operating-Cash-Flow	23.78
	EV-to-EBIT	13.07
	EV-to-EBITDA	10.71
	EV-to-Revenue	2.61
	EV-to-FCF	24.28
	Price-to-GF-Value	0.81
	Price-to-Projected-FCF	1.97
	Price-to-DCF (Earnings Based)	1.27
	Price-to-DCF (FCF Based)	2.17
	Price-to-Median-PS-Value	1.23
	Price-to-Peter-Lynch-Fair-Value	1.45
	Price-to-Graham-Number	1.62
	Price-to-Net-Current-Asset-Value	5.89
	Price-to-Net-Cash	332.23
	Earnings Yield (Greenblatt) %	7.67
	FCF Yield %	4.31
	Forward Rate of Return (Yacktman) %	15.68

Financials

Annual Quarterly TTM

STC:IMP's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Imexpharm Corp Executives

Details

GF Value™: ₫51706.57

STC:IMP

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Medium warning signs with IMP. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil ₫)	2,393,233.286
	EPS (TTM) (₫)	903
	Beta	-
	3-Year Sharpe Ratio	0.75
	3-Year Sortino Ratio	1.47
	Volatility %	18.95
	14-Day RSI	15.25
	14-Day ATR (₫)	709.620933
	20-Day SMA (₫)	45247.5
	12-1 Month Momentum %	-8.98
	52-Week Range (₫)	42050 - 57000
	Shares Outstanding (Mil)	154.01

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Imexpharm Corp Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Imexpharm Corp Stock Events

Financials Calendars

Event	Date	Price (₫)
VND 500.000000 Cash Dividend	2025-06-09	52,000.00 (+0.58%)
2:1 Stock Split	2024-09-17	46,500.00 (-0.21%)
VND 500.000000 Cash Dividend	2024-07-11	37,045.45 (+0.25%)
1.1:1 Stock Split	2024-07-11	37,045.45 (+0.25%)
1.05:1 Stock Split	2023-10-05	30,086.58 (-1.14%)
1.32:1 Stock Split	2020-07-14	19,414.93 (+1.20%)
1.15:1 Stock Split	2018-06-04	17,167.72 (-0.99%)
1.1:1 Stock Split	2017-05-24	16,047.75 (+0.16%)
1.5:1 Stock Split	2014-08-27	10,957.43 (-0.75%)
1.1:1 Stock Split	2012-10-16	6,246.41 (-0.24%)

Show

Entries

Imexpharm Corp Frequently Asked Questions

What is Imexpharm Corp(STC:IMP)'s stock price today?

The current price of STC:IMP is ₫42050.00. The 52 week high of STC:IMP is ₫57000.00 and 52 week low is ₫42050.00.

When is next earnings date of Imexpharm Corp(STC:IMP)?

The next earnings date of Imexpharm Corp(STC:IMP) is .

Does Imexpharm Corp(STC:IMP) pay dividends? If so, how much?

The Dividend Yield % of Imexpharm Corp(STC:IMP) is 1.17% (As of Today), Highest Dividend Payout Ratio of Imexpharm Corp(STC:IMP) was 0.68. The lowest was 0.25. And the median was 0.46. The Forward Dividend Yield % of Imexpharm Corp(STC:IMP) is 0%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
No Press Release

Articles on Imexpharm Corp

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.